IgMs are pentameric or hexametric macro-immunoglobulins and have been highly conserved during evolution, which are the first antibodies secreted following exposure to foreign antigens. The high binding activity of IgM antibodies renders them particularly efficient at binding non-protein antigens such as carbohydrates or lipids as well as antigens present at low levels. Therefore, several naturally occurring IgM antibodies have been explored as therapeutics in clinical trials, while engineered IgM antibodies with enhanced binding and additional functional properties are being evaluated in humans. Therefore, therapeutic IgM attracts more attention from Creative Biolabs, an advanced biotech company focused on the field of therapeutic molecule development. Based on our established and mature platforms, we have gained remarkable achievements in the research of IgM. We are glad to share our experience with our clients over the world.
Learn more: Therapeutic IgM Antibody in Clinical Trials
Add comment
Comments